Zobrazeno 1 - 10
of 92
pro vyhledávání: '"E, Urbieta Sanz"'
Autor:
P Ortiz Fernandez, M Gil Candel, A Martinez Soto, A Herrero Fernandez, P Fernandez-Villacañas Fernandez, I Salar Valverde, M Garcia Coronel, C Pastor Mondéjar, C Caballero Requejo, E Urbieta Sanz
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e788ef08ba84b90319e0ec4bb58bd1f
https://doi.org/10.1136/ejhpharm-2023-eahp.215
https://doi.org/10.1136/ejhpharm-2023-eahp.215
Autor:
P Ortiz Fernandez, E Urbieta Sanz, M Garcia Coronel, P Fernandez-Villacañas Fernandez, A Martinez Soto
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91e2849eec15faf6f164275a90611562
https://doi.org/10.1136/ejhpharm-2023-eahp.227
https://doi.org/10.1136/ejhpharm-2023-eahp.227
Autor:
A Herreros Fernández, E Urbieta Sanz, P Fernandez-Villacañas Fernandez, P Ortiz Fernandez, AM Martinez Soto
Publikováno v:
Section 5: Patient safety and quality assurance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a30a1f6375429d223b599c32bd0641c6
https://doi.org/10.1136/ejhpharm-2023-eahp.319
https://doi.org/10.1136/ejhpharm-2023-eahp.319
Publikováno v:
Pharmaceutical Care España, Vol 19, Iss 4 (2017)
Externí odkaz:
https://doaj.org/article/30d0a03dcd25436493e01fd02bda57cc
Autor:
AM Martínez Soto, M García Coronel, C Pastor Mondéjar, JM Marco Puig, P Ortiz Fernandez, P Fernández-Villacañas Fernández, C Caballero Requejo, L Rentero Redondo, C Iniesta Navalón, I Salar Valverde, E Urbieta Sanz
Publikováno v:
Section 5: Patient safety and quality assurance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a51dea737afaa4f49a67ad656cbd514e
https://doi.org/10.1136/ejhpharm-2022-eahp.266
https://doi.org/10.1136/ejhpharm-2022-eahp.266
Autor:
AM Martínez Soto, M Garcia Coronel, P Ortiz Fernandez, JM Marco Puig, C Pastor Mondéjar, P Fernandez-Villacañas Fernandez, L Rentero Redondo, C Caballero Requejo, C Iniesta Navalon, I Salar Valverde, E Urbieta Sanz
Publikováno v:
Section 5: Patient safety and quality assurance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7dd7f44ab467d641390b1e46d643ce0c
https://doi.org/10.1136/ejhpharm-2022-eahp.268
https://doi.org/10.1136/ejhpharm-2022-eahp.268
Autor:
C Pastor Mondéjar, C Iniesta Navalón, A Martinez Soto, P Ortiz Fernandez, P Ferandez-Villacañas Ferandez, L Rentero Redondo, C Caballero Requejo, M Garcia Coronel, I Salar Valverde, E Urbieta Sanz
Publikováno v:
Section 5: Patient safety and quality assurance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff803a5274a4b6280b898b7e5f3ed348
https://doi.org/10.1136/ejhpharm-2022-eahp.351
https://doi.org/10.1136/ejhpharm-2022-eahp.351
Autor:
C Pastor Mondéjar, C Iniesta Navalón, A Martínez Soto, P Ortiz Fernández, P Ferandez-Villacañas Ferandez, I Salar Valverde, L Rentero Redondo, C Caballero Requejo, M Garcia Coronel, E Urbieta Sanz
Publikováno v:
Section 5: Patient safety and quality assurance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::efee6b8a690f7c8407248174c98af5c6
https://doi.org/10.1136/ejhpharm-2022-eahp.314
https://doi.org/10.1136/ejhpharm-2022-eahp.314
Autor:
C Pastor Mondéjar, C Inista Navalón, A Martinez Soto, P Ortiz Fernandez, P Ferandez-Villacañas Ferandez, I Salar Valverde, L Rentero Redondo, E Urbieta Sanz
Publikováno v:
Section 5: Patient safety and quality assurance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5377fc97e732c0d6335705f8eef13560
https://doi.org/10.1136/ejhpharm-2022-eahp.349
https://doi.org/10.1136/ejhpharm-2022-eahp.349
Autor:
C Iniesta Navalón, C Pastor Mondéjar, M García Coronel, AM Martínez Soto, I Salar Valverde, L Rentero Redondo, Mdc Caballero Requejo, M Gil Candel, P Ortíz Fernández, E Urbieta Sanz, M Onteniente Candela
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Adalimumab is a human monoclonal recombinant antibody whose mechanism of action is mediated by binding specifically to tumour necrosis factor (TNF), neutralising its function. Adalimumab is indicated for the treatment of pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f87ac00c26bdd66fc1ea5c6ab1b9d970
https://doi.org/10.1136/ejhpharm-2021-eahpconf.158
https://doi.org/10.1136/ejhpharm-2021-eahpconf.158